Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.

Rosetta Genomics Ltd. announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's Cancer Origin Test™.
FedMed is a Preferred Provider Organization (PPO) with over 550,000 physicians, 4,000 hospitals and 60,000 Ancillary Care Providers nationwide. It is estimated that more than 40 million Americans have access to FedMed's National Provider Network. FPN is a national direct-contracted preferred provider network that represents approximately four million covered lives. FPN's select provider network is utilized by self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims.

"Rosetta now has executed credentialing agreements with four national U.S. PPOs. Together with Medicare reimbursement, we estimate that the total number of potential covered lives for which the Cancer Origin Test could be adjudicated as 'in-network' exceeds 100 million," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials. This has become increasingly important to our company as we have expanded our U.S. commercial operations and continue to process and bill a growing number of samples.

"These agreements further validate the clinical utility and improved patient outcomes of our Cancer Origin Test and underscore the importance of determining the tumor origin in hard-to-diagnose metastatic cancers, and Cancers of Unknown or Uncertain Primary (CUP). We believe the Cancer Origin Test can help physicians to accurately diagnose tumor origin in order to optimize treatment. The availability and accuracy of our Cancer Origin Test underscores why uncertainty in cancer diagnosis is no longer acceptable," Mr. Berlin added.

A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third-party administrator to provide health care at reduced rates to the insurer's or administrator's clients. Credentialing is a process whereby provider organizations such as physicians, care facilities and ancillary providers (including testing service providers such as Rosetta Genomics) contract directly with the PPO.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics Receives Patent Allowances for MicroRNA-Based Cancer Treatment
Rosetta Genomics receives U.S. patent allowance for microRNA-based ovarian cancer treatment, plus receives two notices of allowance in Israel.
Tuesday, July 12, 2016
Rosetta Genomics Receives Approval from New York State
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.
Saturday, June 25, 2016
Rosetta Receives Approval for RosettaGX Reveal™
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.
Friday, March 04, 2016
Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics Launch Admera’s Sequencing-Based Oncology Tests
The tests will help to predict patient’ responses to drugs based on their personal genetic makeup.
Monday, January 12, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics Announces Agreement with Global Pharmaceutical Company
Leverages Rosetta's microRNA biomarker platform and expertise and global pharmaceutical Company's expertise in Alzheimer's biology and drug development to develop a diagnostic for the early detection of Alzheimer's disease.
Tuesday, August 05, 2014
Rosetta Genomics Announces NGS Research Collaboration with Weizmann Institute
Developing novel methods for next-generation sequencing of small RNAs.
Friday, August 01, 2014
Rosetta Genomics Receives Final New York State Approval
Proprietary microRNA diagnostic for identification of four major subtypes of kidney cancer now available in all 50 U.S. states.
Saturday, July 26, 2014
Rosetta Receives Notice of Allowance for U.S. Patent for Ovarian Cancer Treatment
microRNA therapeutic approach complements company's ovarian cancer predictive biomarker work.
Saturday, July 12, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics, Clait Health Services Enter mRNA Collaboration
Partnership with Clalit Health Services' Rabin Medical Center will develop a non-invasive, microRNA-based, assay for the diagnosis of CAD following kidney transplantation.
Tuesday, March 25, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
50-Year-Old Bacteria Could Be Alternative Treatment Option for Cancer
Researchers have developed a non-toxic strain of Salmonella to penetrate and target cancer cells.
Promising Blood Test Fails to Yield Clues About Best Strategies for Bladder Cancer Treatment
Penn Medicine research challenges previous findings on utility of neutrophil-to-lymphocyte ratio as a biomarker.
Fighting Cancer with the Power of Immunity
Researchers at MIT have used a combination of four different therapies to activate both of the immune system’s two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice.
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Epigenetics and Neural Cell Death
Researchers demonstrate how deregulation of an epigenetic mechanism active in early neurogenesis phases triggers neural cell death.
Gene-Editing Cures Genetic Blood Disorder in Mice
New technology may offer minimally invasive treatment for genetic disorders of the blood.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos